NCT03069001View on ClinicalTrials.gov

Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV

PHASE4CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
HCV
Interventions
DRUG

Sofosbuvir-Simeprevir

-Sofosbuvir-Simeprevir group included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks.

DRUG

Sofosbuvir-Ribavirin

-Sofosbuvir-Ribavirin group included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks.

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT03069001 - Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV | Biotech Hunter | Biotech Hunter